Keel Point LLC Sells 12,184 Shares of Merck & Co., Inc. $MRK

Key Points

• Keel Point LLC reduced its Merck stake by 23.6% in the first quarter, selling 12,184 shares and retaining 39,387 shares valued at approximately $4.74 million. Institutional investors collectively own 76.07% of MRK.
• Merck reported quarterly revenue of $16.29 billion, above analysts’ $15.85 billion estimate, while revenue grew 4.9% year over year. The company also declared a quarterly dividend of $0.85 per share, representing a 2.6% annualized yield.
• Analyst sentiment remains constructive, with 13 Buy ratings and seven Holds producing a consensus “Moderate Buy” rating and a $134.50 price target. MRK recently traded at $130.49, near its 52-week high of $135.05.

Keel Point LLC lessened its position in Merck & Co., Inc. (NYSE:MRK - Free Report) by 23.6% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 39,387 shares of the company's stock after selling 12,184 shares during the period. Keel Point LLC's holdings in Merck & Co., Inc. were worth $4,738,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Kingdom Financial Group LLC. purchased a new stake in shares of Merck & Co., Inc. during the fourth quarter worth about $25,000. Abound Financial LLC purchased a new position in Merck & Co., Inc. during the 4th quarter valued at about $26,000. Prosperity Bancshares Inc bought a new position in Merck & Co., Inc. during the 4th quarter valued at approximately $26,000. High Note Wealth LLC raised its position in Merck & Co., Inc. by 58.9% during the 4th quarter. High Note Wealth LLC now owns 294 shares of the company's stock valued at $31,000 after purchasing an additional 109 shares during the last quarter. Finally, IFC & Insurance Marketing Inc. bought a new position in Merck & Co., Inc. during the 4th quarter valued at approximately $31,000. Hedge funds and other institutional investors own 76.07% of the company's stock.

Merck & Co., Inc. Price Performance

MRK stock opened at $130.49 on Friday. The company has a debt-to-equity ratio of 1.02, a current ratio of 1.30 and a quick ratio of 1.06. Merck & Co., Inc. has a 1 year low of $77.53 and a 1 year high of $135.05. The firm has a 50-day moving average of $123.17 and a 200 day moving average of $118.46. The company has a market cap of $322.28 billion, a P/E ratio of 36.76, a PEG ratio of 5.17 and a beta of 0.19.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last posted its quarterly earnings data on Thursday, April 30th. The company reported ($1.28) earnings per share for the quarter, beating the consensus estimate of ($1.47) by $0.19. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The business had revenue of $16.29 billion for the quarter, compared to analysts' expectations of $15.85 billion. During the same period in the previous year, the firm posted $2.22 EPS. The business's revenue was up 4.9% on a year-over-year basis. On average, sell-side analysts forecast that Merck & Co., Inc. will post 2.74 EPS for the current year.

Merck & Co., Inc. Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, October 7th. Stockholders of record on Tuesday, September 15th will be given a $0.85 dividend. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $3.40 annualized dividend and a dividend yield of 2.6%. Merck & Co., Inc.'s dividend payout ratio is currently 95.77%.

Analyst Upgrades and Downgrades

MRK has been the topic of a number of recent analyst reports. Wells Fargo & Company lifted their price objective on Merck & Co., Inc. from $145.00 to $150.00 and gave the stock an "overweight" rating in a research report on Wednesday, July 8th. Morgan Stanley upped their target price on Merck & Co., Inc. from $112.00 to $113.00 and gave the company an "equal weight" rating in a report on Thursday, July 9th. JPMorgan Chase & Co. raised their price target on Merck & Co., Inc. from $135.00 to $140.00 and gave the stock an "overweight" rating in a research note on Monday, July 13th. Cantor Fitzgerald reaffirmed a "neutral" rating and issued a $120.00 price target on shares of Merck & Co., Inc. in a research note on Monday, July 6th. Finally, Bank of America lifted their price target on shares of Merck & Co., Inc. from $130.00 to $141.00 and gave the company a "buy" rating in a report on Tuesday, June 30th. Thirteen equities research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $134.50.

Trending Headlines about Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck’s launch of subcutaneous Keytruda, known as Qlex, and other lifecycle extensions could preserve the drug’s commercial momentum and support exclusivity through 2039. Recent regulatory approvals, pipeline progress and the acquisitions of Terns and Cidara also broaden the company’s oncology and virology prospects. Merck: Heading Into Q2 Earnings, The Keytruda Cliff Looks Increasingly Less Steep
• Positive Sentiment: Analyst estimates have improved, including Erste Group’s modest increase in its FY2027 EPS forecast to $9.54 from $9.52. Barclays has also forecast strong potential appreciation for MRK, reinforcing the constructive sentiment around the shares. Barclays Forecasts Strong Price Appreciation for Merck & Co., Inc. Stock
• Positive Sentiment: Merck declared a quarterly dividend of $0.85 per share, payable October 7 to shareholders of record September 15. The dividend provides ongoing income support, with a reported annualized yield of about 2.6%.
• Neutral Sentiment: MRK is scheduled to release second-quarter 2026 results before the market opens on August 4. Consensus calls for approximately $16.33 billion in sales and a loss of $0.26 per share, with acquisition costs likely affecting reported earnings. Investors will watch Keytruda demand, Gardasil performance and management’s outlook. Should You Buy, Sell or Hold Merck Stock Ahead of Q2 Earnings?
• Neutral Sentiment: Merck and Wellcome’s Hilleman Laboratories are preparing an experimental Ebola vaccine for clinical trials. The initiative supports Merck’s public-health profile but is unlikely to materially affect near-term financial results. Merck, Wellcome Partner With Global Health Group to Make Ebola Vaccine for Clinical Trials
• Negative Sentiment: After a roughly 17% rally since its latest quarterly results, MRK may already reflect much of the favorable Keytruda and pipeline news. Analysts characterize its longer-term valuation as justified rather than clearly inexpensive, while Gardasil weakness and the approaching earnings event remain risks. Merck Stock Looks Cheap on Cash Flow but Fair on Earnings

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.